Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
There were limited data for nab-paclitaxel and S-1 in pancreatic cancer. To explore the
efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with
resectable pancreatic cancer (stage II and partial stage III defined according to the
National Comprehensive Cancer Network definitions ), we designed this study. This study was a
single-arm single center prospective phase II clinical study. A total of 72 subjects who meet
the criteria will receive neoadjuvant chemotherapy of nab-paclitaxel and S-1 prior to
pancreatectomy. Response was reported according to the Response Evaluation Criteria in Solid
Tumors guidelines (RECIST, version 1.1) .The primary endpoint is objective response rate. The
secondary endpoints include R0/R1 resection rate, disease free survival, overall survival and
safety.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital